Small cell lung cancer: past, present, and future.

@article{Rodriguez2010SmallCL,
  title={Small cell lung cancer: past, present, and future.},
  author={Estelamari Rodriguez and Rogerio C. Lilenbaum},
  journal={Current oncology reports},
  year={2010},
  volume={12 5},
  pages={327-34}
}
Small cell lung cancer (SCLC) accounts for about 10% to 15% of all lung cancers. It is characterized by its rapid doubling time, high rate of dissemination, and increased sensitivity to chemotherapy and radiation. Although the incidence of SCLC has been steadily decreasing over time, it remains a serious public health problem given its aggressive clinical behavior and the lack of effective therapies. This review looks at the evolution of SCLC treatment and the standard treatments that are… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 29 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 56 references

Twenty years of phase III trials for patients with extensive-stage small-cell lung cancer: perceptible progress.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology • 1999
View 6 Excerpts
Highly Influenced

Phase II study of picoplatin as second-line therapy for patients with small-cell lung cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology • 2009
View 1 Excerpt

Salute: a placebocontrolled, double-blind multicenter, randomized, phase II study of bevacizumab in previously untreated extensive-stage small cell lung cancer

D • Spigel, P Townley, D Waterhouse
Presented at the 13th World Conference on Lung Cancer. San Francisco, CA; July 31–August • 2009
View 1 Excerpt

Cediranib (AZD2171) for the treatment of recurrent small cell lung cancer (SCLC): A California Consortium phase II study (NCI # 7097)

SS Ramalingam, PC Mack, EE Vokes
J Clin Oncol 2008, • 2008
View 1 Excerpt

Similar Papers

Loading similar papers…